Print Page     Close Window     

SEC Filings

8-K
SERES THERAPEUTICS, INC. filed this Form 8-K on 10/16/2017
Entire Document
 


Slide 13

Efficacy Analysis: Limited to observed data Endpoint Intent-to-Treat Population: Limited to Observed Data   Placebo / Placebo (N = 10) (%) Vancomycin / SER-287 daily (N = 15) (%) Placebo / SER-287 weekly (N = 14) (%) Vancomycin / SER-287 weekly (N = 14) (%) Clinical Remission: 1/10 (10%) 6/15 (40%) 2/14 (14.3%) 3/14 (21.4%) Difference from placebo (SER-287 minus placebo) 30.0% 4.3%  11.4% p-value 0.1794 0.9999 0.6146 Endoscopic Improvement: 1/10 (10%) 6/15 (40%) 5/14 (35.7%) 4/14 (28.6%) Difference from placebo (SER-287 minus placebo) 30.0% 25.7%  18.6% p-value 0.1794 0.3408 0.3577 Clinical Response: 6/10 (60%) 9/15 (60%) 6/14 (42.9%) 4/14 (28.6%) Difference from placebo (SER-287 minus placebo) 0.0% -17.1%  -31.4% p-value 0.9999 0.6802 0.2112 Initial top-line reported results Top line SER-287 Phase 1b data disclosed in October 2, 2017 press release


© Seres Therapeutics. All Rights Reserved.